Refractory patients, niche indication expansions, and geographical reach offer room for growth in an otherwise crowded epilepsy market.
This report addresses the following questions:
- Why do leading antiepileptic drugs retain a large amount of brand loyalty, despite loss of exclusivity and cheap direct competition? - Who are the future market leaders in the treatment of epilepsy? - Which patient subgroups will have the largest impact on epilepsy sales? - What are the drug companies' strategies when penetrating a highly crowded market to achieve profitability? - What are epilepsy's unmet needs that could be addressed by drug companies?